Screening for HFE and Iron Overload

ABSTRACT

Type 1 hereditary hemochromatosis is a common disorder of iron overload occurring in individuals homozygous for the C282Y HFE gene mutation. It can be a progressive and fatal condition. Early detection and phlebotomy prior to the onset of cirrhosis can reduce morbidity and normalize life expectancy. It is readily identified through biochemical testing for iron overload using serum transferrin saturation and genetic testing for C282Y homozygosity. General population screening has been waived in preference to targeting high-risk groups such as first-degree relatives of affected individuals and those with clinical features suggestive of iron loading. This screening strategy is likely to continue until uncertainties regarding the natural history of the disease, age-related penetrance, and management of asymptomatic individuals are clarified. Potential ethical, legal, and psychosocial issues arising through application of genetic screening programs also must be resolved prior to implementation of general population screening programs.

KEYWORDS

Hemochromatosis - screening - penetrance

REFERENCES

• 1 Bomford A. Genetics of hemochromatosis.  Lancet. 2002;  360 1673-1681
• 2 Njajou O T, Alizadeh B Z, Van Duijn C M. Is genetic screening for haemochromatosis worthwhile?.  Eur J Epidemiol. 2004;  19 101-108
• 3 Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease.  N Engl J Med. 2004;  350 2383-2397
• 4 Olynyk J K, Cullen D J, Aquilia S et al.. A population based study of clinical expression of the hemochromatosis gene.  N Engl J Med. 1999;  341 718-724
• 5 Adams P C, Reboussin D M, Barton J C et al.. Hemochromatosis and iron-overload screening in a racially diverse population.  N Engl J Med. 2005;  352 1769-1778
• 6 Olynyk J K. Hereditary haemochromatosis: diagnosis and management in the gene era.  Liver. 1999;  19 73-80
• 7 Jazwinska E C, Cullen L M, Busfield F et al.. Hemochromatosis and HLA-H.  Nat Genet. 1996;  14 249-251
• 8 Willis G, Wimperis J Z, Lonsdale R et al.. Incidence of liver disease in people with HFE mutations.  Gut. 2000;  46 401-404
• 9 Gochee P A, Powell L W, Cullen D J et al.. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation.  Gastroenterology. 2002;  122 646-651
• 10 Bacon B R. Hemochromatosis: diagnosis and management.  Gastroenterology. 2001;  120 718-725
• 11 Roetto A, Papanikolaou G, Politou M et al.. Mutant antimicrobial peptide is associated with severe juvenile hemochromatosis.  Nat Genet. 2003;  33 21-22
• 12 Papanikolaou G, Samuels M E, Ludwig E H et al.. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis.  Nat Genet. 2004;  36 77-82
• 13 Camaschella C, Roetto A, Cali A et al.. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22.  Nat Genet. 2000;  25 14-15
• 14 Njajou O T, Vaessen N, Joosse M et al.. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis.  Nat Genet. 2001;  28 213-214
• 15 Montosi G, Donovan A, Totaro A et al.. Autosomal-dominant haemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene.  J Clin Invest. 2001;  108 619-623
• 16 Siah C W, Trinder D, Olynyk J K. Iron overload.  Clin Chim Acta. 2005;  358 24-36
• 17 Gitlin J D. Aceruloplasminemia.  Pediatr Res. 1998;  44 271-276
• 18 Hayashi A, Wada Y, Suzuki T et al.. Studies on familial hypotransferrinemia: unique clinical course and molecular pathology.  Am J Hum Genet. 1993;  53 201-213
• 19 Vautier G, Murray M, Olynyk J K. Hereditary haemochromatosis: detection and management.  Med J Aust. 2001;  175 418-421
• 20 Dubois S, Kowdley K. Targeted screening for hereditary haemochromatosis in high-risk groups.  Aliment Pharmacol Ther. 2004;  20 1-14
• 21 Bulaj Z J, Ajioka R S, Phillips J D et al.. Disease-related conditions in relatives of patients with hemochromatosis.  N Engl J Med. 2000;  343 1529-1535
• 22 Delatycki M B, Powell LW, Allen KJ. Hereditary hemochromatosis genetic testing of at-risk children: what is the appropriate age?.  Genet Test. 2004;  8 98-103
• 23 Olynyk J K, Hagan S E, Cullen D J, Beilby J. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study.  Mayo Clin Proc. 2004;  79 309-313
• 24 Andersen R V, Tybjærg-Hansen A, Appleyard M et al.. Hemochromatosis mutations in the general population: iron overload progression rate.  Blood. 2004;  103 2914-2919
• 25 Krawczak M, Cooper D N, Schmidtke J. Estimating the efficacy and efficiency of cascade genetic screening.  Am J Hum Genet. 2001;  69 361-370
• 26 El-Serag H B, Inadomi J M, Kowdley K V. Screening for hereditary hemochromatosis in siblings and children of affected patients. A cost-effectiveness analysis.  Ann Intern Med. 2000;  132 261-269
• 27 Adams P C, Kertesz A E, Valberg L S. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness.  Hepatology. 1995;  22 1720-1727
• 28 Cadet E, Capron D, Gallet M. Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases?.  J Med Genet. 2005;  42 390-395
• 29 Hanson E H, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology.  Am J Epidemiol. 2001;  154 193-206
• 30 Rochette J, Pointon J, Fisher C A et al.. Multicentre origin of hemochromatosis gene (HFE) mutations.  Am J Hum Genet. 1999;  64 1056-1062
• 31 Khoury M J, Burke W, Thomson E J. Genetics and public health: a framework for the integration of human genetics into public health practices. In: Khoury MJ, Burke W, Thomson EJ Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease. New York, NY; Oxford University Press 2000: 3-24
• 32 Burke W, Thomson E, Khoury M J et al.. Hereditary hemochromatosis: gene discovery and its implications for population-based screening.  JAMA. 1998;  280 172-178
• 33 US Preventative Task Force .Guide to Clinical Preventative Services: Report of the US Preventative Services Task Force. 2nd ed. Baltimore, MD; US Preventative Task Force 1996: 231-246
• 34 Wilson J M, Junger G. The Principles and Practice of Screening for Disease. Public Health Paper 34. Geneva, Switzerland; World Health Organization 1968
• 35 Burke W, Coughlin S S, Lee N C, Weed D L. Application of population screening principles to genetic screening for adult-onset conditions.  Genet Test. 2001;  5 201-211
• 36 Cogswell M E, McDonnell S M, Khoury M J. Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening.  Ann Intern Med. 1998;  129 971-979
• 37 EASL International Consensus Conference on Hemochromatosis . III. Jury document.  J Hepatol. 2000;  33 496-504
• 38 Adams P C, Reboussin D M, Leiendecker-Foster C et al.. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101 168 participants in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.  Clin Chem. 2005;  51 1048-1052
• 39 McLaren C E, McLachlan G J, Halliday J W et al.. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of haemochromatosis.  Gastroenterology. 1998;  114 543-549
• 40 McDonnell S M, Phatak P D, Felitti V et al.. Screening for hemochromatosis in primary care settings.  Ann Intern Med. 1998;  129 962-970
• 41 Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary haemochromatosis.  Gastroenterology. 1996;  110 1107-1119
• 42 Bacon B R, Sadiq S A. Hereditary hemochromatosis: presentation and diagnosis in the 1990s.  Am J Gastroenterol. 1997;  92 784-789
• 43 Waalen J, Felitti V, Gelbert T et al.. Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene.  Mayo Clin Proc. 2002;  77 522-530
• 44 Beutler E, Felitti V J, Koziol J A et al.. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA.  Lancet. 2002;  359 211-218
• 45 McCune C A, Al-Jader L N, May A et al.. Hereditary hemochromatosis: only 1% of adult HFE C282Y homozygotes in South Wales have a clinical diagnosis of iron overload.  Hum Genet. 2002;  111 538-543
• 46 Asberg A, Hveem K, Thorstensen E et al.. High prevalence and low morbidity in an unselected population of 65,238 persons.  Scand J Gastroenterol. 2001;  36 1108-1115
• 47 Powell L, Dixon J, Ramm G, Anderson G J. The penetrance of HFE-associated hemochromatosis as assessed by liver biopsy in subjects identified by health checks, family screening or population screening.  Hepatology. 2004;  40 574A
• 48 Leggett B A, Brown N N, Bryant S J et al.. Factors affecting the concentrations of ferritin in serum in a healthy Australian population.  Clin Chem. 1990;  36 1350-1355
• 49 Bhavnani M, Lloyd D, Bhattacharyyra A et al.. Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase.  Gut. 2000;  46 707-710
• 50 Poullis A, Moodie S J, Ang L et al.. Routine transferrin saturation measurement in liver clinic patients increases detection of hereditary haemochromatosis.  Ann Clin Biochem. 2003;  40 521-527
• 51 Bacon B R, Olynyk J K, Brunt E M et al.. HFE genotype in patients with hemochromatosis and other liver diseases.  Ann Intern Med. 1999;  130 953-962
• 52 Green R M, Flamm S. AGA Medical Position Statement: Evaluation of Liver Chemistry Tests.  Gastroenterology. 2002;  123 1367-1384
• 53 Kazemi-Shirazi L, Datz C, Maier-Dobersberger T et al.. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C.  Gastroenterology. 1999;  116 127-134
• 54 Bugianesi E, Manzini P, Antico S et al.. Relative contribution of iron overload, HFE mutations and insulin resistance to fibrosis in non-alcoholic fatty liver.  Hepatology. 2004;  39 179-187
• 55 Lauret E, Rodrigues M, Gonzales S et al.. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma.  Am J Gastroenterol. 2002;  97 1016-1021
• 56 Turnbull A J, Michison H C, Pearson R T et al.. The prevalence of hereditary hemochromatosis in a diabetic population.  QJM. 1997;  90 271-275
• 57 Phelps G, Chapman I, Hall P et al.. Prevalence of genetic haemochromatosis among diabetic patients.  Lancet. 1989;  2 233-234
• 58 George D K, Evans R M, Crofton R W et al.. Testing of haemochromatosis in the diabetic clinic.  Ann Clin Biochem. 1995;  32 521-526
• 59 Njajou O T, Alizadeh B Z, Vaessen N et al.. The role of hemochromatosis C282Y and H63D gene mutations in type 2 diabetes: findings from the Rotterdam Study and meta-analysis [letter].  Diabetes Care. 2002;  25 2112-2113
• 60 Mainous A G, King D E, Pearson W S, Garr D. Is elevated serum transferrin saturation associated with the development of diabetes?.  J Fam Pract. 2002;  51 933-936
• 61 Ellervik C, Mandrup-Poulsen T, Nordestgaard B G et al.. Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study.  Lancet. 2001;  358 1405-1409
• 62 Hramiak I M, Finegood D T, Adams P C. Factors affecting glucose tolerance in hereditary hemochromatosis.  Clin Invest Med. 1997;  20 110-118
• 63 Willis G, Scott D G, Jennings B A et al.. HFE mutations in an inflammatory arthritis population.  Rheumatology. 2002;  41 176-179
• 64 Olynyk J, Hall P, Ahern M et al.. Prevalence of genetic haemochromatosis in patients with peripheral arthritis.  Aust N Z J Med. 1994;  24 22-25
• 65 Cauza E, Hanusch-Enserer U, Etemad M et al.. HFE genotyping demonstrates a significant incidence of hemochromatosis in undifferentiated arthritis.  Clin Exp Rheumatol. 2005;  23 7-12
• 66 Ross J M, Kowalchuk R M, Shaulinsky J et al.. Association of heterozygous hemochromatosis C282Y gene mutation with hand osteoarthritis.  J Rheumatol. 2003;  30 121-125
• 67 Sherrington C A, Knuiman M W, Divitini M L et al.. A population-based study of the relationship between mutations in the hemochromatosis (HFE) gene and arthritis.  J Gastroenterol Hepatol. 2005;  , (in press)
• 68 Timms A E, Sathananthan R, Bradbury L et al.. Genetic testing for hemochromatosis in patients with chondrocalcinosis.  Ann Rheum Dis. 2002;  61 745-747
• 69 Phatak P D, Guzman G, Woll J E et al.. Cost-effectiveness of screening for hereditary hemochromatosis.  Arch Intern Med. 1994;  154 769-776
• 70 Delatycki M B, Allen K J, Nisselle A E et al.. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis.  Lancet. 2005;  366 314-316
• 71 Balan V, Baldus W, Fairbanks V, Michels V. Screening for hemochromatosis: a cost-effectiveness study based on 12, 258 patients.  Gastroenterology. 1994;  107 453-459
• 72 Adams P C, Gregor J C, Kertesz A E et al.. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database.  Gastroenterology. 1995;  109 177-188
• 73 Asberg A, Tretli S, Hveem K, Bjerve K S. Benefit of population-based screening for phenotypic hemochromatosis in young men.  Scand J Gastroenterol. 2002;  37 1212-1219
• 74 Patch C, Roderick P, Rosenberg W. Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis.  J Hepatol. 2005;  43 149-155
• 75 Adams P C. Screening for haemochromatosis-producing or preventing illness?.  Lancet. 2005;  366 269-271
• 76 Olynyk J K, Trinder D, Milward E. Hereditary haemochromatosis: to screen or not to screen.  J Hepatol. 2005;  43 9-10
• 77 Clayton E W. Ethical, legal, and social implications of genomic medicine.  N Engl J Med. 2003;  349 562-569
• 78 Beauchamp T L, Childress J F. Principles of Biomedical Ethics. 5th ed. New York; Oxford University Press 2001
• 79 Nisselle A E, Delatycki M B, Collins V et al.. Implementation of HaemScreen, a workplace-based genetic screening program for hemochromatosis.  Clin Genet. 2004;  65 358-367
• 80 American Society of Human Genetics Board of Directors . American College of Medical Genetics Board of Directors. . Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents.  Am J Hum Genet. 1995;  57 1233-1241
• 81 Nelson R M, Botkjin J R, Kodish E D et al.. Committee on Bioethics. Ethical issues with genetic testing in pediatrics.  Pediatrics. 2001;  107 1451-1455
• 82 Committee on Genetics . Molecular genetic testing in pediatric practice: a subject review.  Pediatrics. 2000;  106 1494-1497
• 83 Alper J S, Geller L N, Barash C I et al.. Genetic discrimination and screening for hemochromatosis.  J Public Health Policy. 1994;  15 345-358
• 84 Shaheen N J, Lawrence L B, Bacon B R et al.. Insurance, employment and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage.  Am J Gastroenterol. 2003;  98 1175-1180
• 85 Genetic Information Nondiscrimination Act of 2005 (S.306). Available at: http://thomas.loc.gov Accessed June 14, 2005
• 86 Delatycki M, Allen K, Williamson R. Insurance agreement to facilitate genetic testing [letter].  Lancet. 2002;  359 1433
• 87 Godard B, Raeburn S, Pembrey M. Genetic information and testing in insurance and employment: technical, social and ethical issues.  Eur J Hum Genet. 2003;  11 (suppl 2) S123-S142
• 88 European Society of Human Genetics . Genetic information and testing in insurance and employment: technical, social and ethical issues. Recommendations of the European Society of Human Genetics.  Eur J Hum Genet. 2003;  11 (suppl 2) S11-S12
• 89 The American Society of Human Genetics . Statement on informed consent for genetic research.  Am J Hum Genet. 1996;  59 471-474
• 90 Allen K, Williamson R. Should we genetically test everyone for haemochromatosis?.  J Med Ethics. 1999;  25 209-214